APTO-253

Aptose Biosciences announced financial results for Q3 2024, highlighting a net loss decrease to $7.0 million. The company secured a $10 million loan from Hanmi to support tuspetinib development, showcasing its potential in AML triplet therapies. Aptose faces challenges with Nasdaq compliance, aiming to address stockholders' equity and minimum bid price requirements. Key milestones include initiating TUS+VEN+AZA triplet dosing in newly diagnosed AML patients and reporting data from ongoing studies.